Geneva, Switzerland - Allosteric modulation company Addex Pharmaceuticals (SWX: ADXN) announced today that ADX10059 did not reduce acute anticipatory anxiety in a small Phase IIa study in patients with dental anxiety. However, some signs of anxiolytic activity were observed. Development of ADX10059 for gastroesophageal reflux disease (GERD) and migraine is continuing as planned.
